Analysts Viewpoint An Analysis of Mersana Therapeutics Inc (MRSN)’s Potential Price Growth Mersana Therapeutics Inc’s filing revealed that its VP, Chief Accounting Officer Mandelia Ashish unloaded Company’s shares for reported $2061.0 on
Stock Earnings Analyzing Mersana Therapeutics Inc (MRSN) After Recent Trading Activity Mersana Therapeutics Inc’s recent filing unveils that its VP, Chief Accounting Officer Mandelia Ashish unloaded Company’s shares for reported $2061.0